The Case for High Returns: A Study of the Pharmaceutical Industry by Taylor, David & Russell, Faculty Advisor, David
Illinois Wesleyan University
Digital Commons @ IWU
John Wesley Powell Student Research
Conference 1995, 6th Annual JWP Conference
Apr 22nd, 10:00 AM - Apr 21st, 4:00 PM
The Case for High Returns: A Study of the
Pharmaceutical Industry
David Taylor
Illinois Wesleyan University
David Russell, Faculty Advisor
Illinois Wesleyan University
Follow this and additional works at: http://digitalcommons.iwu.edu/jwprc
This Event is brought to you for free and open access by The Ames Library, the Andrew W. Mellon Center for Curricular and Faculty
Development, the Office of the Provost and the Office of the President. It has been accepted for inclusion in Digital Commons @ IWU by
the faculty at Illinois Wesleyan University. For more information, please contact digitalcommons@iwu.edu.
©Copyright is owned by the author of this document.
David Taylor and David Russell, Faculty Advisor, "The Case for High Returns: A Study of the Pharmaceutical Industry"
(April 22, 1995). John Wesley Powell Student Research Conference. Paper 6.
http://digitalcommons.iwu.edu/jwprc/1995/posters/6
The Case for High Returns: 
A Study of the Pharmaceutical Industry 
David Taylor and David Russe1I*, Department of Business Administration 
This project analyzes the abnormal returns that the larger pharmaceutical 
firms generate by studying such variables as R&D expenditures, demographics, and 
market structure and their effect on the abnormal returns pharmaceutical firms 
generate for their stockholders. A company's abnormal return is the difference 
between the return on that company's common stock and the market return. The 
principal hypothesis is that investment in research and development, the aging 
population, and increasing generic market share, significantly affect the abnormal 
returns generated by pharmaceutical firms. This project will also examine how 
other aspects of the pharmaceutical industry distinguish it from other industries 
and how these characteristics may account for the abnormal returns that 
pharmaceutical firms generate for their shareholders. 
